Actinium Pharmaceuticals Received U.S. Patent Extending Into 2040 And Covers Methods Using Iomab-ACT For Conditioning Patients Prior To The Administration Of Gene-edited Hematopoietic Stem Cell Therapy To Treat Non-malignant Disorders
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals has received a U.S. patent extending into 2040, covering methods using Iomab-ACT for conditioning patients prior to gene-edited hematopoietic stem cell therapy for non-malignant disorders.
August 01, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals has received a U.S. patent extending into 2040, covering methods using Iomab-ACT for conditioning patients prior to gene-edited hematopoietic stem cell therapy for non-malignant disorders.
The new patent extends the exclusivity of Actinium Pharmaceuticals' Iomab-ACT method until 2040, potentially enhancing its market position and future revenue streams. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100